Please ensure Javascript is enabled for purposes of website accessibility Deaths spur Norway concern at Covid vaccine safety for vulnerable elderly | #vacation | #seniors | #elderly – Active Lifestyle Media

Follow or share

VacationDeaths spur Norway concern at Covid vaccine safety for vulnerable elderly | #vacation | #seniors | #elderly

Deaths spur Norway concern at Covid vaccine safety for vulnerable elderly | #vacation | #seniors | #elderly

[ad_1]

Norway has expressed increasing concern about the safety of the Pfizer Inc vaccine for elderly people with serious underlying health conditions after raising their estimate of the number who died after receiving inoculations to 29.

The latest figure adds six to the number of known fatalities in Norway, and broadens the age group thought to be affected to 75 years and up, from 80 years.

While it’s unclear exactly when the deaths occurred, Norway has given at least one dose to about 42,000 people and focused on those considered most at risk if they contract the virus, including the elderly.

Until Friday, the vaccine produced by Pfizer and BioNTech SE was the only one available in Norway, and “all deaths are thus linked to this vaccine”, the Norwegian Medicines Agency said in a written response to Bloomberg on Saturday.

“There are 13 deaths that have been assessed, and we are aware of another 16 deaths that are currently being assessed,” the agency said. All the reported deaths related to “elderly people with serious basic disorders”, it said. “Most people have experienced the expected side-effects of the vaccine, such as nausea and vomiting, fever, local reactions at the injection site, and worsening of their underlying condition.”

Official reports of allergic reactions have been rare as governments rush to roll out vaccines to try to contain the global pandemic. US authorities reported 21 cases of severe allergic reactions from December 14th-23rd after administration of about 1.9 million initial doses of the Pfizer vaccine.

[ad_2]

Click Here For The Original Source

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Leave a Reply